Try our Advanced Search for more refined results

US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

April 19, 2013

AbbVie Deutschland GmbH & Co. v. Janssen Biotech, Inc.

Track this case

Case Number:

13-1338

Court:

Appellate - Federal Circuit

Nature of Suit:

830 Patent Infringement (Fed. Question)

Companies

Sectors & Industries:

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. July 01, 2014

    Fed. Circ. Upholds Ruling Nixing AbbVie Antibody Patents

    The Federal Circuit on Tuesday affirmed a lower court's ruling that two antibody patents that AbbVie Inc. accused Johnson & Johnson unit Janssen Biotech Inc.'s psoriasis treatment Stelara of infringing are invalid for lacking an adequate written description.

1 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login